Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

Heart Transplant Failure and Rejection Clinical Trial

Official title:

A Phase 1 Study of Daratumumab-SC for Reduction of Circulating Antibodies in Patients With High Allosensitization Awaiting Heart Transplantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04610320
• Other study ID #: 53476
• Status: Completed
• Phase: Phase 1
• Start date: July 1, 2021
• Est. completion date: January 26, 2024

Study information

• Verified date: March 2024
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test whether Daratumumab-SC, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation. These preformed antibodies limit the number of donor hearts that are compatible for the patients. If Daratumumab-SC can effectively remove preformed, donor-specific antibodies, then highly allosensitized patients will have more compatible hearts available to them, potentially decreasing transplant waitlist time and reducing mortality.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: January 26, 2024
• Est. primary completion date: January 26, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Participant is on an active list for a heart transplant.
• Participant has a high level of allosensitization, defined as a calculated PRA (panel of reactive antibodies) of 50%, based on their antibody status at the time of entry into the study.
• Ability to understand and willingness to sign an informed consent form prior to any study-related procedures.
• Women of childbearing potential must have a negative pregnancy test at screening.
• Both male and female patients must use effective methods of birth control, must not donate eggs or sperm during the course of the study and for 3 months after stopping daratumumab-SC.
• Adequate bone marrow function.
• Adequate renal function (estimated GFR greater than or equal to 15 mL/min by the Cockcroft-Gault formula).

Exclusion Criteria:

• History of allergy or intolerance to daratumumab or Daratumumab-SC.
• Prior diagnosis of myeloma or light chain amyloidosis.
• Active infection.
• Women who are pregnant or breastfeeding.
• Ongoing desensitization treatment with another agent. Subjects are excluded if they

have received:

• a. IVIG within 30 days of enrollment.
• b. Proteasome inhibitor within 60 days of enrollment.
• c. Rituximab within 180 days of enrollment.
• Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study.
• Contraindication to herpes zoster prophylaxis.
• Known to be seropositive for human immunodeficiency virus (HIV).
• Known to be seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.
• Known to be seropositive for hepatitis C (except in the setting of a sustained virologic response (SVR), defined as aviremia at least 12 weeks after completion of antiviral therapy).
• Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 is <50% of predicted normal.
• Known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.
• Known history of human immunodeficiency virus (HIV).
• History of blood product transfusion within 60 days of enrollment, or anticipated need for blood product transfusion during the course of the study.
• Moderate-severe liver dysfunction.

Related Conditions & MeSH terms

• Allosensitization
• Heart Transplant Failure and Rejection

Intervention

Drug:
• Daratumumab-SC
>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.

Locations

Country	Name	City	State
United States	Stanford Health Care	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Ronald Witteles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the level of preformed HLA antibodies before and after Daratumumab-SC treatment, based on the absolute difference in PRA levels before and after treatment.	Will assess the difference in PRA percentage (defined based on those HLA antibodies which have a mean fluorescence intensity [MFI] >3000) at baseline versus Week 12.	Baseline and Week 12 (or the last measurement prior to heart transplantation, whichever is earlier).
Secondary	Percent MFI change for each individual preformed HLA antibody at Week 6.	Will measure the percent change in the MFI of each circulating preformed HLA antibody from baseline to Week 6 or the time of heart transplantation (whichever is earlier).	Baseline and Week 6 (or the last measurement prior to heart transplantation, whichever is earlier).
Secondary	Percent MFI change for each individual preformed HLA antibody at Week 12.	Will measure the percent change in the MFI of each circulating preformed HLA antibody from baseline to Week 12 or the time of heart transplantation (whichever is earlier).	Baseline and Week 12 (or the last measurement prior to heart transplantation, whichever is earlier).
Secondary	Percent MFI change for each individual preformed HLA antibody at Week 15.	Will measure the percent change in the MFI of each circulating preformed HLA antibody from baseline to Week 15 or the time of heart transplantation (whichever is earlier).	Baseline and Week 15 (or the last measurement prior to heart transplantation, whichever is earlier).
Secondary	Change in the level of preformed HLA antibodies before and after Daratumumab-SC treatment, based on the absolute difference in PRA levels at baseline and Week 6.	Will assess the difference in PRA percentage (defined based on those HLA antibodies which have a mean fluorescence intensity [MFI] >3000) at baseline versus Week 6.	Baseline and Week 6 (or the last measurement prior to heart transplantation, whichever is earlier).